Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
DBV Technologies SA (DBVT) is a clinical-stage biopharmaceutical leader advancing epicutaneous immunotherapy (EPIT) through its innovative Viaskin platform, targeting food allergies with non-invasive precision. This page aggregates all essential updates on the company’s clinical progress, regulatory milestones, and strategic initiatives.
Investors and stakeholders gain centralized access to critical developments including phase trial results, FDA/EMA interactions, and partnership announcements. Each update is curated to provide actionable insights into DBVT’s pioneering work in allergy treatment while maintaining rigorous scientific accuracy.
Key coverage areas include Viaskin efficacy data, patent developments, and manufacturing scalability updates. The resource is designed to help users track the company’s progress from clinical research to potential commercialization without requiring cross-platform monitoring.
Bookmark this page for streamlined tracking of DBV Technologies’ advancements in redefining food allergy management through its unique skin-based immunotherapy approach.
Monthly Voting Rights Announcement
As of March 31, 2021, the total number of shares for the company stands at 54,936,687. The total number of voting rights is reported at 54,936,687 gross and 54,876,099 net, indicating shares without voting rights have been accounted for. This announcement complies with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers and relates to disclosures on the NYSE Euronext Paris market.
DBV Technologies, a clinical-stage biopharmaceutical company, has appointed Ms. Viviane Monges as the new Chair of its Audit Committee, effective March 23, 2021. Monges, a member of the Board since May 2019, brings extensive financial expertise from her roles at various pharmaceutical companies. The company also announced a forthcoming Ordinary and Extraordinary General Meeting on May 19, 2021, to vote on the appointment of a new independent director to the Audit Committee. DBV is focused on developing its Viaskin technology to treat food allergies.
DBV Technologies has filed its first Annual Report on Form 10-K and its 2020 Universal Registration Document, both covering the fiscal year ended December 31, 2020. These filings are available on the company's website and regulatory authorities. Additionally, DBV will be included in the SBF 120 Index on Euronext starting March 22, 2021, which consists of the largest 120 companies by market capitalization. This inclusion reflects DBV’s growing stature within the market as it focuses on developing innovative therapies for food allergies through its Viaskin technology.
As of February 28, 2021, the company reported a total of 54,936,687 shares outstanding. The total number of voting rights is listed as 54,936,687 gross and 54,888,687 net. The net total accounts for shares without voting rights, offering a clear picture of shareholder influence. This information complies with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies reported its 2020 financial results, revealing a net loss of $(159.6) million, improved from $(172.0) million in 2019. Operating income dropped 23.3% to $11.3 million, while operating expenses decreased to $170.1 million due to cost-cutting measures. DBV ended 2020 with cash equivalents of $196.4 million, supporting operations until at least mid-2022. Additionally, the company is advancing its Viaskin Peanut trials in the US and EU, positioning itself for potential approvals. DBV will host a conference call to discuss these developments.
DBV Technologies announced its participation in the H.C. Wainwright Global Life Sciences Conference taking place on March 9-10, 2021. CEO Daniel Tassé will present during the event. A webcast of the presentation will be available on the company’s website starting March 9 at 7:00 a.m. ET. DBV Technologies focuses on developing Viaskin™, a proprietary platform for epicutaneous immunotherapy, targeting food allergies, with ongoing trials for Viaskin Peanut. The company is headquartered in Montrouge, France, and trades on Euronext Paris (DBV) and Nasdaq (DBVT).
DBV Technologies has announced a rescheduling of its financial results conference call for the full year 2020, now set for March 11, 2021, at 5:00 PM ET. The call will provide a financial update and a corporate overview. The event can be accessed through various teleconferencing numbers and will also be available via a live webcast on the company’s website. DBV Technologies is focused on developing Viaskin™, an innovative immunotherapy platform aimed at addressing food allergies through epicutaneous delivery methods.
DBV Technologies will report its full year 2020 financial results on March 4, 2021. The clinical-stage biopharmaceutical company will hold a conference call and live audio webcast at 5:00 p.m. ET to discuss the results and provide a corporate update. Interested parties can access the call via specified teleconferencing numbers and also via a live webcast available on the company's website. The company is focused on developing Viaskin™, a proprietary technology for treating food allergies through a non-invasive method.
DBV Technologies (Euronext: DBV, Nasdaq: DBVT) announced its participation in the AAAAI 2021 Congress from February 26 to March 1. The company will present findings from a post-hoc analysis of its 12-month Phase 3 PEPITES trial, focusing on the effectiveness of its DBV712 (Viaskin™ Peanut) patch in reducing allergic reactions in children aged 4 to 11. They will also showcase pre-clinical data regarding cashew allergies. Additionally, DBV is sponsoring the FIT Networking Lounge to foster connections among AAAAI fellows.
DBV Technologies has appointed Michele F. Robertson as the new Chief Legal Officer, effective immediately. She brings over 15 years of legal expertise in the biopharma sector, previously serving as General Counsel at Mallinckrodt Pharmaceuticals. Robertson will support DBV's scientific development, regulatory efforts, and corporate governance while facilitating interactions with the FDA. DBV aims to advance its Viaskin™ Peanut product, focusing on meeting the needs of food-allergic patients. The company is positioned for regulatory clarity and strategic growth.
FAQ
What is the current stock price of Dbv Technologies S A (DBVT)?
What is the market cap of Dbv Technologies S A (DBVT)?
